Did you know?

On average, Wall Street analysts predict that Compass Pathways 's share price could reach $57.25 by Aug 22, 2024. The average Compass Pathways stock price prediction …Shares of the Peter Thiel -backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling ...Zacks forecast a loss of 55 cents per share. The company had zero revenue, as its main product, COMP360, is still in trials. ... Compass Pathways stock is in an IPO base with a 47.39 buy point.EF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research Report) today and set a price target of $38.00... EF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research ...Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ... Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has entered into a securities purchase agreement with a select group of healthcare specialist investors for the private placement of (i) 16,076,750 …Compass shares are also dragging in late 2023, down 26.3% on a year-to-date basis. The U.K.-based biotech, which specializes in psilocybin research for treating depression, recently landed $285 ...CMPS - Compass Pathways Plc - ADR Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)The average Compass stock price prediction forecasts a potential upside of 35.39% from the current COMP share price of $2.43. What is COMP's forecast return on equity (ROE) for 2023-2026? ( NYSE : COMP ) forecast ROE is N/A , which is considered weak . COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the …COMPASS Pathways (CMPS) Insider Trading Activity 2023. S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. Turned down for a loan, business owners look to family and even crowdsourcing to get money to grow. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) 13 crew members missing after a cargo ship …Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers barFinancial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).WebCMPS. COMPASS Pathways plc. 5.83. -0.22. -3.64%. COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to ...Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...WebThe only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations....CMPS With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate...While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months.WebCompass, Inc. (NYSE:COMP) announced its quarterly earnings data on Monday, November, 6th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.35 billion.Web... Stock Price Chart Interactive Chart > · Price chart for CMPS. COMPASS Pathways PLC ADR (CMPS) Company Bio. COMPASS Pathways plc operates as a mental health care ...UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval. With the treatment’s …In the last 3 months, 5 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $50.6 with a high of $120.00 and a low of $19.00. Below is a ...Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target....CMPS Compass Pathways (CMPS) has grabbed the interest of Canaccord Genuity analyst Sumant Kulkarni, who gave the biotech company an $80 price target....View a financial market summary for CMPS including stock price quote, trading volume, volatility, options volume, statistics, and other important company ...LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that new positive data demonstrating the potential of COMP360 psilocybin therapy in depression have …Discover the reasons why Compass Pathways Plc (CMPS) stock is experiCOMPASS Pathways is a mental healthcare company that s The average price target is $46.83, with a high forecast of $120.00 and a low forecast of $19.00. ... The current consensus among 5 investment analysts is to buy stock in COMPASS Pathways. This Buy consensus rating has held steady for over two years. Past Monthly Recommendations.CMPS stock has been performing well on August 16, 2023, with positive price forecasts and a consensus among analysts to buy the stock. According to data from CNN Money, the 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 21.00. Stock Price Forecast. The 5 analysts offering 12-month pr Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ...Web COMPASS Pathways is a business that is trying to treat a

Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...Web*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. COMPASS Pathways Analyst Opinions. All. All ...Here are some of the best psychedelic sector stocks generating a buzz among investors: — Atai Life Sciences NV (ticker: ATAI) — GH Research PLC ( GHRS) — Compass Pathways PLC ( CMPS ...COMPASS Pathways Stock forecast & analyst price target predictions based on 6 analysts offering 12-months price targets for 5Y6 in the last 3 months.

Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...Stock Price Forecast. The 3 analysts offering 12-month price forecasts for GameStop Corp have a median target of 18.75, with a high estimate of 20.00 and a low estimate of 6.00. The median ...Mar 2, 2022 · COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ... …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Step 3: Place your order and invest in CMPS. Place your order by . Possible cause: (Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5,.